Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study-Reference-Cited by-同舟云学术

Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study

Published:2017-02-21 Issue:6 Volume:27 Page:1031-1035
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Lopalco Giuseppe¹,Emmi Giacomo²,Gentileschi Stefano³,Guerriero Silvana⁴,Vitale Antonio³,Silvestri Elena²,Becatti Matteo⁵,Cavallo Iacopo²,Fabiani Claudia⁶,Frediani Bruno³,Iannone Florenzo¹,Cantarini Luca³

Affiliation:

1. Department of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Bari, Italy;

2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;

3. Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy;

4. Department of Neurosciences and Sense Organs, University of Bari, Bari, Italy;

5. Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy;

6. Department of Ophthalmology, Humanitas Research Hospital, Milan, Italy

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2017.1285857

Reference25 articles.

1. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

2. Behçet's syndrome: disease manifestations, management, and advances in treatment